Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 92

1.

MicroRNA-17 acts as a tumor chemosensitizer by targeting JAB1/CSN5 in triple-negative breast cancer.

Wang S, Oh DY, Leventaki V, Drakos E, Zhang R, Sahin AA, Resetkova E, Edgerton ME, Wu W, Claret FX.

Cancer Lett. 2019 Nov 28;465:12-23. doi: 10.1016/j.canlet.2019.08.016. Epub 2019 Aug 29.

2.

MicroRNAs as Therapeutic Targets in Nasopharyngeal Carcinoma.

Wang S, Claret FX, Wu W.

Front Oncol. 2019 Aug 13;9:756. doi: 10.3389/fonc.2019.00756. eCollection 2019. Review.

3.

Thermodynamic evidence of giant salt deposit formation by serpentinization: an alternative mechanism to solar evaporation.

Debure M, Lassin A, Marty NC, Claret F, Virgone A, Calassou S, Gaucher EC.

Sci Rep. 2019 Aug 12;9(1):11720. doi: 10.1038/s41598-019-48138-9.

4.

AP-1 Transcription Factors as Regulators of Immune Responses in Cancer.

Atsaves V, Leventaki V, Rassidakis GZ, Claret FX.

Cancers (Basel). 2019 Jul 23;11(7). pii: E1037. doi: 10.3390/cancers11071037. Review.

5.

The novel Jab1 inhibitor CSN5i-3 suppresses cell proliferation and induces apoptosis in human breast cancer cells.

Xiao H, Claret FX, Shen Q.

Neoplasma. 2019 May 23;66(3):481-486. doi: 10.4149/neo_2018_181016N772. Epub 2019 Mar 7.

PMID:
30868895
6.

A four-methylated mRNA signature-based risk score system predicts survival in patients with hepatocellular carcinoma.

Wang Y, Ruan Z, Yu S, Tian T, Liang X, Jing L, Li W, Wang X, Xiang L, Claret FX, Nan K, Guo H.

Aging (Albany NY). 2019 Jan 10;11(1):160-173. doi: 10.18632/aging.101738.

7.

Jab1/Cops5 contributes to chemoresistance in breast cancer by regulating Rad51.

Liu G, Yu M, Wu B, Guo S, Huang X, Zhou F, Claret FX, Pan Y.

Cell Signal. 2019 Jan;53:39-48. doi: 10.1016/j.cellsig.2018.09.010. Epub 2018 Sep 20.

PMID:
30244171
8.

hsa‑miR‑24 suppresses metastasis in nasopharyngeal carcinoma by regulating the c‑Myc/epithelial‑mesenchymal transition axis.

Su B, Xu T, Bruce JP, Yip KW, Zhang N, Huang Z, Zhang G, Liu FF, Liang J, Yang H, Claret FX.

Oncol Rep. 2018 Nov;40(5):2536-2546. doi: 10.3892/or.2018.6690. Epub 2018 Sep 7.

9.

Thermodynamic and crystallographic model for anion uptake by hydrated calcium aluminate (AFm): an example of molybdenum.

Marty NCM, Grangeon S, Elkaïm E, Tournassat C, Fauchet C, Claret F.

Sci Rep. 2018 May 21;8(1):7943. doi: 10.1038/s41598-018-26211-z.

10.

Deciphering mineralogical changes and carbonation development during hydration and ageing of a consolidated ternary blended cement paste.

Claret F, Grangeon S, Loschetter A, Tournassat C, De Nolf W, Harker N, Boulahya F, Gaboreau S, Linard Y, Bourbon X, Fernandez-Martinez A, Wright J.

IUCrJ. 2018 Jan 19;5(Pt 2):150-157. doi: 10.1107/S205225251701836X. eCollection 2018 Mar 1.

11.

Jab1/COPS5 as a Novel Biomarker for Diagnosis, Prognosis, Therapy Prediction and Therapeutic Tools for Human Cancer.

Liu G, Claret FX, Zhou F, Pan Y.

Front Pharmacol. 2018 Feb 27;9:135. doi: 10.3389/fphar.2018.00135. eCollection 2018. Review.

12.

Autophagy in the "inflammation-carcinogenesis" pathway of liver and HCC immunotherapy.

Yu S, Wang Y, Jing L, Claret FX, Li Q, Tian T, Liang X, Ruan Z, Jiang L, Yao Y, Nan K, Lv Y, Guo H.

Cancer Lett. 2017 Dec 28;411:82-89. doi: 10.1016/j.canlet.2017.09.049. Epub 2017 Oct 5. Review.

PMID:
28987386
13.

Evidence of Multiple Sorption Modes in Layered Double Hydroxides Using Mo As Structural Probe.

Ma B, Fernandez-Martinez A, Grangeon S, Tournassat C, Findling N, Claret F, Koishi A, Marty NCM, Tisserand D, Bureau S, Salas-Colera E, Elkaïm E, Marini C, Charlet L.

Environ Sci Technol. 2017 May 16;51(10):5531-5540. doi: 10.1021/acs.est.7b00946. Epub 2017 Apr 27.

PMID:
28417632
14.

Jab1/Csn5-Thioredoxin Signaling in Relapsed Acute Monocytic Leukemia under Oxidative Stress.

Zhou F, Pan Y, Wei Y, Zhang R, Bai G, Shen Q, Meng S, Le XF, Andreeff M, Claret FX.

Clin Cancer Res. 2017 Aug 1;23(15):4450-4461. doi: 10.1158/1078-0432.CCR-16-2426. Epub 2017 Mar 7.

15.

Quantitative X-ray pair distribution function analysis of nanocrystalline calcium silicate hydrates: a contribution to the understanding of cement chemistry.

Grangeon S, Fernandez-Martinez A, Baronnet A, Marty N, Poulain A, Elkaïm E, Roosz C, Gaboreau S, Henocq P, Claret F.

J Appl Crystallogr. 2017 Feb 1;50(Pt 1):14-21. doi: 10.1107/S1600576716017404. eCollection 2017 Feb 1.

16.

Mutual regulation of microRNAs and DNA methylation in human cancers.

Wang S, Wu W, Claret FX.

Epigenetics. 2017 Mar 4;12(3):187-197. doi: 10.1080/15592294.2016.1273308. Epub 2017 Jan 6. Review.

17.

Novel biomarkers of nasopharyngeal carcinoma metastasis risk identified by reverse phase protein array based tumor profiling with consideration of plasma Epstein-Barr virus DNA load.

Xu T, Su B, Huang P, Wei W, Deng Y, Sehgal V, Wang D, Jiang J, Zhang G, Li A, Yang H, Claret FX.

Proteomics Clin Appl. 2017 May;11(5-6). doi: 10.1002/prca.201600090. Epub 2016 Dec 29.

PMID:
27883284
18.

RBM24 suppresses cancer progression by upregulating miR-25 to target MALAT1 in nasopharyngeal carcinoma.

Hua WF, Zhong Q, Xia TL, Chen Q, Zhang MY, Zhou AJ, Tu ZW, Qu C, Li MZ, Xia YF, Wang HY, Xie D, Claret FX, Song EW, Zeng MS.

Cell Death Dis. 2016 Sep 1;7(9):e2352. doi: 10.1038/cddis.2016.252.

19.

Stat3 contributes to cancer progression by regulating Jab1/Csn5 expression.

Pan Y, Wang S, Su B, Zhou F, Zhang R, Xu T, Zhang R, Leventaki V, Drakos E, Liu W, Claret FX.

Oncogene. 2017 Feb 23;36(8):1069-1079. doi: 10.1038/onc.2016.271. Epub 2016 Aug 15.

20.

Structure of nanocrystalline calcium silicate hydrates: insights from X-ray diffraction, synchrotron X-ray absorption and nuclear magnetic resonance.

Grangeon S, Claret F, Roosz C, Sato T, Gaboreau S, Linard Y.

J Appl Crystallogr. 2016 Apr 12;49(Pt 3):771-783. eCollection 2016 Jun 1.

21.

Hsa-miR-24-3p increases nasopharyngeal carcinoma radiosensitivity by targeting both the 3'UTR and 5'UTR of Jab1/CSN5.

Wang S, Pan Y, Zhang R, Xu T, Wu W, Zhang R, Wang C, Huang H, Calin CA, Yang H, Claret FX.

Oncogene. 2016 Nov 24;35(47):6096-6108. doi: 10.1038/onc.2016.147. Epub 2016 May 9.

22.

Down-regulation of the cyclin-dependent kinase inhibitor p57 is mediated by Jab1/Csn5 in hepatocarcinogenesis.

Guo H, Jing L, Cheng Y, Atsaves V, Lv Y, Wu T, Su R, Zhang Y, Zhang R, Liu W, Rassidakis GZ, Wei Y, Nan K, Claret FX.

Hepatology. 2016 Mar;63(3):898-913. doi: 10.1002/hep.28372. Epub 2016 Jan 14.

PMID:
26606000
23.

Mineral precipitation-induced porosity reduction and its effect on transport parameters in diffusion-controlled porous media.

Chagneau A, Claret F, Enzmann F, Kersten M, Heck S, Madé B, Schäfer T.

Geochem Trans. 2015 Sep 3;16:13. doi: 10.1186/s12932-015-0027-z. eCollection 2015.

24.

Constitutive control of AKT1 gene expression by JUNB/CJUN in ALK+ anaplastic large-cell lymphoma: a novel crosstalk mechanism.

Atsaves V, Zhang R, Ruder D, Pan Y, Leventaki V, Rassidakis GZ, Claret FX.

Leukemia. 2015 Nov;29(11):2162-72. doi: 10.1038/leu.2015.127. Epub 2015 May 19.

25.

Clinical implications of hepatitis B viral infection in Epstein-Barr virus-associated nasopharyngeal carcinoma.

Xu T, Huang Z, Deng Y, Wang S, Su B, Wei W, Wang D, Jiang J, Li A, Zhang G, Yang H, Claret FX, Hu W.

J Clin Virol. 2015 Mar;64:64-71. doi: 10.1016/j.jcv.2014.11.024. Epub 2014 Nov 27.

PMID:
25728081
26.

Molecular markers to assess short-term disease local recurrence in nasopharyngeal carcinoma.

Xu T, Su B, Wang C, Wang S, Huang H, Pan Y, Wang D, Wei W, Claret FX, Yang H.

Oncol Rep. 2015 Mar;33(3):1418-26. doi: 10.3892/or.2015.3739. Epub 2015 Jan 20.

27.

Involvement of microRNA-24 and DNA methylation in resistance of nasopharyngeal carcinoma to ionizing radiation.

Wang S, Zhang R, Claret FX, Yang H.

Mol Cancer Ther. 2014 Dec;13(12):3163-74. doi: 10.1158/1535-7163.MCT-14-0317. Epub 2014 Oct 15.

28.

The oncogenic JUNB/CD30 axis contributes to cell cycle deregulation in ALK+ anaplastic large cell lymphoma.

Atsaves V, Lekakis L, Drakos E, Leventaki V, Ghaderi M, Baltatzis GE, Chioureas D, Jones D, Feretzaki M, Liakou C, Panayiotidis P, Gorgoulis V, Patsouris E, Medeiros LJ, Claret FX, Rassidakis GZ.

Br J Haematol. 2014 Nov;167(4):514-23. doi: 10.1111/bjh.13079. Epub 2014 Aug 22.

PMID:
25145835
29.

Personalized drug combinations to overcome trastuzumab resistance in HER2-positive breast cancer.

Vu T, Sliwkowski MX, Claret FX.

Biochim Biophys Acta. 2014 Dec;1846(2):353-65. doi: 10.1016/j.bbcan.2014.07.007. Epub 2014 Jul 25. Review.

30.

Effects of charging on the chromophores of dissolved organic matter from the Rio Negro basin.

Yan M, Korshin GV, Claret F, Croué JP, Fabbricino M, Gallard H, Schäfer T, Benedetti MF.

Water Res. 2014 Aug 1;59:154-64. doi: 10.1016/j.watres.2014.03.044. Epub 2014 Apr 19.

PMID:
24793113
31.

Emerging roles of Jab1/CSN5 in DNA damage response, DNA repair, and cancer.

Pan Y, Yang H, Claret FX.

Cancer Biol Ther. 2014 Mar 1;15(3):256-62. doi: 10.4161/cbt.27823. Epub 2014 Feb 4. Review.

32.

X-ray diffraction: a powerful tool to probe and understand the structure of nanocrystalline calcium silicate hydrates.

Grangeon S, Claret F, Linard Y, Chiaberge C.

Acta Crystallogr B Struct Sci Cryst Eng Mater. 2013 Oct;69(Pt 5):465-73. doi: 10.1107/S2052519213021155. Epub 2013 Sep 19.

33.

Dickkopf-1 is a key regulator of myeloma bone disease: opportunities and challenges for therapeutic intervention.

Zhou F, Meng S, Song H, Claret FX.

Blood Rev. 2013 Nov;27(6):261-7. doi: 10.1016/j.blre.2013.08.002. Epub 2013 Sep 2. Review.

34.

Curcumin analogue T83 exhibits potent antitumor activity and induces radiosensitivity through inactivation of Jab1 in nasopharyngeal carcinoma.

Pan Y, Wang M, Bu X, Zuo Y, Wang S, Wang D, Liu Q, Su B, Xu T, Wang C, Claret FX, Yang H.

BMC Cancer. 2013 Jul 1;13:323. doi: 10.1186/1471-2407-13-323.

35.

Novel roles of reactive oxygen species in the pathogenesis of acute myeloid leukemia.

Zhou F, Shen Q, Claret FX.

J Leukoc Biol. 2013 Sep;94(3):423-9. doi: 10.1189/jlb.0113006. Epub 2013 May 28. Review.

36.

Stat3 inhibitor Stattic exhibits potent antitumor activity and induces chemo- and radio-sensitivity in nasopharyngeal carcinoma.

Pan Y, Zhou F, Zhang R, Claret FX.

PLoS One. 2013;8(1):e54565. doi: 10.1371/journal.pone.0054565. Epub 2013 Jan 29.

37.

Insights into the regulation of the human COP9 signalosome catalytic subunit, CSN5/Jab1.

Echalier A, Pan Y, Birol M, Tavernier N, Pintard L, Hoh F, Ebel C, Galophe N, Claret FX, Dumas C.

Proc Natl Acad Sci U S A. 2013 Jan 22;110(4):1273-8. doi: 10.1073/pnas.1209345110. Epub 2013 Jan 3.

38.

Targeting Jab1/CSN5 in nasopharyngeal carcinoma.

Pan Y, Claret FX.

Cancer Lett. 2012 Dec 30;326(2):155-60. doi: 10.1016/j.canlet.2012.07.033. Epub 2012 Aug 4. Review.

39.

Suppression of Jab1/CSN5 induces radio- and chemo-sensitivity in nasopharyngeal carcinoma through changes to the DNA damage and repair pathways.

Pan Y, Zhang Q, Atsaves V, Yang H, Claret FX.

Oncogene. 2013 May 30;32(22):2756-66. doi: 10.1038/onc.2012.294. Epub 2012 Jul 16.

40.

Trastuzumab: updated mechanisms of action and resistance in breast cancer.

Vu T, Claret FX.

Front Oncol. 2012 Jun 18;2:62. doi: 10.3389/fonc.2012.00062. eCollection 2012.

41.

Jab1/CSN5 negatively regulates p27 and plays a role in the pathogenesis of nasopharyngeal carcinoma.

Pan Y, Zhang Q, Tian L, Wang X, Fan X, Zhang H, Claret FX, Yang H.

Cancer Res. 2012 Apr 1;72(7):1890-900. doi: 10.1158/0008-5472.CAN-11-3472. Epub 2012 Feb 20.

42.

Discriminating factors affecting incorporation: comparison of the fate of Eu3+-Cm3+ in the Sr carbonate-sulfate system.

Holliday K, Chagneau A, Schmidt M, Claret F, Schäfer T, Stumpf T.

Dalton Trans. 2012 Apr 7;41(13):3642-7. doi: 10.1039/c2dt12425d. Epub 2012 Feb 13.

PMID:
22327306
43.

Phosphatases: the new brakes for cancer development?

Zhang Q, Claret FX.

Enzyme Res. 2012;2012:659649. doi: 10.1155/2012/659649. Epub 2011 Oct 31.

44.

The role of p27(Kip1) in dasatinib-enhanced paclitaxel cytotoxicity in human ovarian cancer cells.

Le XF, Mao W, He G, Claret FX, Xia W, Ahmed AA, Hung MC, Siddik ZH, Bast RC Jr.

J Natl Cancer Inst. 2011 Sep 21;103(18):1403-22. doi: 10.1093/jnci/djr280. Epub 2011 Aug 2.

45.

Metal speciation in landfill leachates with a focus on the influence of organic matter.

Claret F, Tournassat C, Crouzet C, Gaucher EC, Schäfer T, Braibant G, Guyonnet D.

Waste Manag. 2011 Sep-Oct;31(9-10):2036-45. doi: 10.1016/j.wasman.2011.05.014. Epub 2011 Jun 25.

PMID:
21705206
46.

Stat3 and CCAAT/enhancer binding protein beta (C/EBP-beta) regulate Jab1/CSN5 expression in mammary carcinoma cells.

Shackleford TJ, Zhang Q, Tian L, Vu TT, Korapati AL, Baumgartner AM, Le XF, Liao WS, Claret FX.

Breast Cancer Res. 2011 Jun 20;13(3):R65. doi: 10.1186/bcr2902.

47.

Activation of the p53 pathway by the MDM2 inhibitor nutlin-3a overcomes BCL2 overexpression in a preclinical model of diffuse large B-cell lymphoma associated with t(14;18)(q32;q21).

Drakos E, Singh RR, Rassidakis GZ, Schlette E, Li J, Claret FX, Ford RJ Jr, Vega F, Medeiros LJ.

Leukemia. 2011 May;25(5):856-67. doi: 10.1038/leu.2011.28. Epub 2011 Mar 11.

48.

Expression of serine 194-phosphorylated Fas-associated death domain protein correlates with proliferation in B-cell non-Hodgkin lymphomas.

Drakos E, Leventaki V, Atsaves V, Schlette EJ, Lin P, Vega F, Miranda RN, Claret FX, Medeiros LJ, Rassidakis GZ.

Hum Pathol. 2011 Aug;42(8):1117-24. doi: 10.1016/j.humpath.2010.11.002. Epub 2011 Feb 11.

49.

JAB1/CSN5: a new player in cell cycle control and cancer.

Shackleford TJ, Claret FX.

Cell Div. 2010 Oct 18;5:26. doi: 10.1186/1747-1028-5-26.

50.

Essential roles of Jab1 in cell survival, spontaneous DNA damage and DNA repair.

Tian L, Peng G, Parant JM, Leventaki V, Drakos E, Zhang Q, Parker-Thornburg J, Shackleford TJ, Dai H, Lin SY, Lozano G, Rassidakis GZ, Claret FX.

Oncogene. 2010 Nov 18;29(46):6125-37. doi: 10.1038/onc.2010.345. Epub 2010 Aug 30.

Supplemental Content

Loading ...
Support Center